What happened?
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 16.7% in the morning session after the company reported its financial results for the calendar third quarter of 2026 that exceeded Wall Street expectations and projected an improvement in free cash flow.
In details disclosed in the release, top-line performance was led by Sample Management Solutions, where revenue rose 9% to $94 million, offsetting flat revenue of $73 million in Multiomics. Azenta reported adjusted gross margin expanded 50 basis points to 47.2%, aided by favorable mix, cost-efficiency measures, and operating leverage, which helped cushion quality remediation expenses in Automated Stores.
Looking to fiscal 2027, the company projected revenue to between $648 million and $660 million, reflecting 3% to 5% organic growth. The company expects adjusted EBITDA margin to expand 200 to 250 basis points—absorbing 100 basis points of dilution from its Elegen licensing agreements and SynPlexity acquisition—alongside a projected 25% improvement in free cash flow relative to fiscal 2026. For Azenta, positive quarterly cash generation signals that cost streamlining and portfolio refocusing are gaining traction. If underlying operating leverage offsets integration dilution from recent gene synthesis deals, steady expansion across sample management provides the visibility needed to support sustained valuation re-rating.
Is now the time to buy Azenta? Access our full analysis report here, it’s free.
What is the market telling us
Azenta’s shares are extremely volatile and have had 36 moves greater than 5% over the last year. But moves this big are rare even for Azenta and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 23 days ago when the stock gained 3.5% on the news that investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.
Capital has increasingly shifted toward defensive sectors, which are widely recognized for delivering resilient earnings and dependable cash flows during times of macroeconomic uncertainty as reported by Axios. Beyond this safe-haven rotation, market sentiment was bolstered by growing expectations that Democrats could gain ground in upcoming midterm elections. Analysts indicated that a political shift could lead to the rollback or easing of federal healthcare spending cuts implemented under President Trump's 2025 spending bill. A potential reversal of those reductions is viewed positively by investors, as it would protect vital funding streams and preserve demand for pharmaceuticals, clinical care, and related healthcare services. With regulatory headwinds potentially diminishing and macroeconomic caution lingering, healthcare equities saw broad-based buying across the industry.
Azenta is up 42.9% since the beginning of the year, and at $47.74 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Azenta’s shares 5 years ago would now be looking at only $419.22.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.